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Zn is an essential mineral. The role of Zn in atherosclerosis is not clear. Epidemiological studies,
which have reported contradictory results, are limited by the use of serum Zn levels as a marker of
intake. We assessed the association of toenail Zn, which integrates dietary Zn intake over 3 to 12
months, with the risk of a first myocardial infarction. Toenail Zn concentrations were determined
by neutron activation analysis in the European multi-centre case–control study on antioxidants,
myocardial infarction and breast cancer. This multi-centre case–control study included 684 cases
and 724 controls from eight European countries and Israel. Toenail Zn levels of controls (adjusted
for age and study centre) were positively associated with age, a-tocopherol and Se, but not with
additional dietary variables or with classical risk factors for CHD. Average toenail Zn was
106·0 mg/kg in cases (95 % CI 103·1, 108·9) and 107·5 mg/kg in controls (95 % CI 104·5,
110·7). After controlling for cardiovascular risk factors and for centre, the adjusted odds ratios
of myocardial infarction for quintiles 2–5 of toenail Zn with respect to the first quintile were
0·97 (95 % CI 0·59, 1·58), 1·15 (95 % CI 0·72, 1·85), 0·91 (95 % CI 0·56, 1·50), and 0·85 (95 %
CI 0·52, 1·39). The P for trend was 0·45. In conclusion toenail Zn levels (reflecting long-term
dietary intake) were not significantly associated with acute myocardial infarction.
Case–control studies: Heavy metals: Zinc: Myocardial infarction: Neutron activation
analysis
Zn is an essential mineral necessary for maintenance of
membrane structure and function. There are over 300
known enzymes that require Zn for catalytic, co-catalytic
or structural functions (Prasad, 1993). Clinical manifes-
tations of Zn deficiency include growth retardation, male
hypogonadism, skin changes, mental lethargy and suscepti-
bility to infection. Zn deficiency also results in increased
membrane cholesterol and altered cell membrane skeleton
protein composition (Bettger & O’Dell, 1981; King, 1990;
Vallee & Falchuk, 1993; Chesters, 1997).
The effect of Zn in the pathogenesis of atherosclerosis is
not clear. Epidemiological studies have reported contradic-
tory results and are limited by the use of serum Zn levels as
a marker of Zn intake. Nevertheless, an anti-atherogenic
effect of Zn has been hypothesized due to its antioxidant
and membrane-stabilizing properties (Henning et al.
1996, 1999).
To evaluate the association of Zn with the risk of myo-
cardial infarction, we measured toenail Zn in the partici-
pants in the European multi-centre case–control study on
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antioxidants, myocardial infarction and breast cancer
(EURAMIC) (Kardinaal et al. 1993, 1997) and assessed
the association with the risk of a first acute myocardial
infarction.
Methods
Design and subjects
The target population of the EURAMIC study consisted of
men 70 years of age or younger, native residents of Finland
(Helsinki), Germany (Berlin), Israel (Jerusalem),
The Netherlands (Zeist), Norway (Sarpsborg), Russia
(Moscow), UK (Edinburgh, Scotland), Switzerland
(Zu¨rich), and Spain (Granada and Ma´laga). Subjects were
excluded if they had a previous diagnosis of myocardial
infarction, drug or alcohol abuse, major psychiatric dis-
orders, if they were institutionalized, or had modified their
dietary pattern in the past year (Kardinaal et al. 1993).
Cases were men with a first acute myocardial infarction,
confirmed by characteristic electrocardiographic changes
and serum enzymes, hospitalized within 24 h from the
onset of symptoms. They were recruited from the coronary
care units of participating hospitals. Controls were men
without a history of myocardial infarction, recruited from
the study population catchment area and frequency-matched
for age in 5-year intervals. In Finland, Israel, Germany,
Scotland and Switzerland, random sampling from local
population registers was used for control selection. In
Russia and in the two Spanish centres, controls were selected
from patients admitted to the hospital for disorders not
known to be associated with dietary factors (renal colic,
non-infectious prostatism, acute appendicitis, non-infectious
ear disease, hernia, volvulus, rectal or anal disease except
cancer, haemorrhoids, or chronic infection). In The Nether-
lands, controls were selected from the catchment area of
the patient’s general practitioner, and in Norway they were
selected by inviting friends and relatives of the case.
Cases and controls were recruited concurrently during
1991 and 1992. Informed consent was obtained from study
participants in accordance with the ethical standards of the
responsible local committees on human experimentation.
Data collection
Information on smoking habits, history of hypertension, and
diabetes was collected for all subjects by standard question-
naires (Rose et al. 1982). Socio-economic status, family his-
tory and alcohol intake were assessed through locally
developed questionnaires by administered interview.
Toenail clippings from all ten toes were collected within
8 weeks of inclusion in the study and were stored in small
plastic bags at room temperature (Kardinaal et al. 1997).
The mean weight of the samples was 53·9 (SD 39·1) mg.
A non-fasting venous blood sample was drawn for
cholesterol analysis. In cases, these samples were drawn
within 24 h of hospital admission or onset of symptoms.
Serum samples were transported on dry ice at 2568C to
the reference laboratories.
Subcutaneous adipose tissue was taken from the buttock,
by needle aspiration, within 7 d of hospital admission.
Samples were stored at 2708C and were analysed in a cen-
tral laboratory.
Laboratory analyses
The Zn concentration in toenails was measured by instru-
mental neutron activation analysis at the Interfaculty Reac-
tor Institute of the Delft University of Technology in Delft,
The Netherlands (Alfassi, 1994; Bode & de Goeij, 1998;
Bode, 2000). Toenail clippings were irradiated for 4 h in
a thermal flux of 5 £ 1012 neutrons/s per cm2. After a
decay time of 21 d, the g radiation of Zn was measured
in a well-type Ge-detector. For each centre, samples from
cases and controls were analysed together and randomly
distributed across batches. Personnel at the Interfaculty
Reactor Institute were blinded with respect to the case or
control status of the samples.
The CV, as an expression of inter-assay variation for Zn,
was 3·2 % for fifty samples of reference material NIST SRM-
1577b ‘Bovine Liver’ (NIST, Gaithersburg, MD, USA) with
a certified value of 127^16 (1 SD) mg/kg and also for fifty-
two samples of reference material BCR-CRM-414 ‘Trace
elements in plankton’ (IRMM, Retieseweg, Belgium) with
a certified value of 112^3 (1 SD) mg/kg.
Serum total cholesterol levels were determined enzymi-
cally (Boehringer-Mannheim GmbH, Mannheim, Germany).
HDL-cholesterol was determined after precipitation with
dextran sulfate and MgCl2. Cholesterol determinations
were performed at the National Public Health Institute in
Helsinki, Finland.
a-Tocopherol and b-carotene were determined in the
adipose tissue after saponification by reverse-phase HPLC
and spectrophotometric detection (Van Vliet et al. 1991).
Statistical methods
Since the distributions of Zn in all centres were right-
skewed, log-transformations were used. The results are
reported as geometric means (mg/kg). The distribution of
Zn in controls was used to compute cut-off points and
medians for quintiles of exposure. The levels of cardiovas-
cular risk factors across quintiles of Zn were compared
among controls by ANOVA and x2 tests (Snedecor &
Cochran, 1989). The centre-specific and adjusted overall
mean case–control differences of Zn and 95 % CI were esti-
mated by linear regression (Hosmer & Lemeshow, 2000).
For multivariate analysis, the association of Zn with the
risk of myocardial infarction was estimated with multiple
logistic regression. Adjusted relative risks were estimated
as odds ratios in quintiles 2–5 using the lowest quintile
as the reference category, and trend tests across quintiles
of Zn were computed by including in the logistic models
an ordinal variable with the median for each quintile of
Zn. All P values reported were two-tailed. Statistical ana-
lyses were performed using STATA (StataCorp, 1999)
and the SAS package (SAS Institute, 1990).
Results
Compared with controls, cases had significantly higher
BMI, lower HDL-cholesterol levels, and were more
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likely to be hypertensive, diabetic, smokers, or to have a
family history of CHD (Table 1). We believe that the
lower concentration of total cholesterol among cases
most probably reflects the effect of acute myocardial
infarction. Therefore total cholesterol was not further con-
sidered in case–control comparisons.
Average toenail Zn was 106·0 mg/kg in cases (95 % CI
103·1, 108·9) and 107·5 mg/kg in controls (95 % CI 104·5,
110·7). The relative combined uncertainty in the individual
measurements varied between 2 to 4 %, whereas the limit of
detection for Zn in toenail samples was estimated at
approximately 5 mg/kg.
Zinc levels and risk factors among controls
Jerusalem and Zu¨rich had the highest average concen-
trations of Zn (geometric means of 128·1 and 115·3 mg/
kg, respectively), while Zeist, Sarpsborg and Helsinki
had the lowest (geometric means of 101·6, 102·5 and
102·8 mg/kg, respectively). The maximum difference
between centres was only 27 % (Table 2). The age- and
centre-adjusted overall geometric mean of Zn in controls
was 107·5 mg/kg (95 % CI 104·5, 110·7). The distribution
of Zn in each centre and across centres was relatively
narrow, with a CV of 8·4 % for the total of the control
sample, and below 10 % in all centres except in the case
of Jerusalem.
Table 3 shows the association of toenail Zn levels with
other coronary risk factors among controls, adjusted for
age and centre. Zn was associated with age, a-tocopherol
and Se, whereas no significant association was found in
relation to other factors (BMI, total cholesterol, HDL-
cholesterol, alcohol, b-carotene, history of hypertension,
smoking, diabetes, socio-economic status or family history
of CHD).
Toenail zinc and risk of myocardial infarction
Zn levels were lower in cases compared with controls in
most centres (Table 2), but the difference was small and
statistically non-significant (except in Jerusalem). There
was no significant effect modification by centre on the
association of Zn with myocardial infarction. After adjust-
ing for age and centre, BMI, HDL-cholesterol, smoking,
Table 1. Comparison of cardiovascular risk factors between cases and controls
(Mean values and standard deviations)
Cases (n 684) Controls (n 724)
Risk factor Mean SD Mean SD P value
Age (years) 54·7 8·9 53·2 9·3 0·002
BMI (kg/m2) 26·5 3·9 25·9 3·4 0·004
Total cholesterol (mmol/l) 5·5 1·1 5·6 1·1 0·110
HDL-cholesterol (mmol/l) 0·9 0·3 1·1 0·3 ,0·001
History of hypertension (%) 26·0 17·4 ,0·001
Smoking (% current smokers) 61·4 37·5 ,0·001
Diabetes mellitus (%) 8·4 3·9 ,0·001
Alcohol use (g/d) 18·2 17·8 0·750
Family history of CHD (%) 57·6 45·3 ,0·001
Low socio-economic status (%) 25·1 20·8 0·036
Table 2. Zinc levels and case–control ratios of zinc levels (mg/kg) in toenails
(Mean values and 95 % confidence intervals)
n Cases Controls Zn case:Zn control
Centre Cases Controls Mean 95 % CI Mean 95 % CI Ratio 95 % CI
Berlin 75 97 104·6 98·1, 111·5 108·3 101·1, 116·1 0·95 0·86, 1·05
Edinburgh 39 25 103·7 96·1, 111·9 112·9 101·4, 125·7 0·92 0·81, 1·05
Granada 55 52 109·4 95·7, 125·0 110·1 97·8, 124·1 0·99 0·83, 1·18
Helsinki 56 62 102·7 98·6, 107·0 102·8 98·6, 107·1 1·00 0·95, 1·06
Jerusalem 57 59 103·1 95·8, 111·0 128·1 105·7, 155·3 0·80 0·65, 0·99
Ma´laga 94 100 110·2 100·2, 121·3 102·9 96·5, 109·7 1·07 0·96, 1·20
Moscow 92 97 110·5 99·2, 123·1 103·8 95·4, 113·0 1·07 0·92, 1·23
Sarpsborg 96 101 101·8 98·0, 105·9 102·5 98·8, 106·5 0·99 0·94, 1·05
Zeist 64 57 99·3 94·0, 104·9 101·6 95·3, 108·5 0·98 0·90, 1·06
Zu¨rich 56 74 113·8 100·0, 129·5 115·3 102·4, 130·1 0·96 0·80, 1·15
Overall 684 724 106·0 103·1, 108·9 107·5 104·5, 110·7 0·99* 0·95, 1·03
0·96† 0·91, 1·01
0·96‡ 0·92, 1·01
* Age- and centre-adjusted.
† Further adjusted by BMI, HDL-cholesterol, history of hypertension, smoking, alcohol intake, diabetes, family history of CHD,
a-tocopherol, b-carotene and Se.
‡ Further adjusted by socio-economic status.
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alcohol drinking, history of hypertension, diabetes and
family history of CHD, cases had lower concentrations
of Zn by 4 % (95 % CI 9, 21). These estimations were
further adjusted by a-tocopherol, b-carotene and Se, and
then by socio-economic status, but controlling for these
variables did not materially affect the estimates.
The association of increased Zn with lower risk of myo-
cardial infarction was examined in more detail by evaluat-
ing the odds ratios of disease by quintiles of Zn (Table 4).
Age- and centre-adjusted analysis showed a 19 % reduction
in the risk of myocardial infarction for the fifth quintile, but
no significant trend was found (P¼0·25). Significant inter-
actions between Zn and other trace elements or fatty acids
were not detected (data not shown). Further adjustments
for BMI, HDL-cholesterol, smoking, alcohol drinking, his-
tory of hypertension, diabetes, family history of CHD,
a-tocopherol, b-carotene and Se, and then by socio-econ-
omic status, tended to slightly move the estimates towards
the null value.
Discussion
In this large, international case–control study, the concen-
tration of Zn in the toenails of study participants was
slightly lower among cases of myocardial infarction com-
pared with controls. However, this difference was not stat-
istically significant.
There are some factors that should be pointed out for the
appropriate appraisal of our findings. First, the study was
specifically designed to evaluate the association of toenail
heavy metals with the risk of myocardial infarction.
Second, toenails and adipose tissue samples were originally
collected in cases shortly after the myocardial infarction.
These measurements are thus unlikely to be affected by
the manifestation of disease, a common limitation of retro-
spective case–control studies. Finally, in contrast to heavy
metal levels in serum or plasma, which may show substan-
tial day-to-day variability, toenail clippings provide a
measure of relatively long-term intake of trace elements,
reflecting average exposure to heavy metals over the pre-
vious 3–12 months (Hunter, 1998). Moreover, there is evi-
dence of particularly good reproducibility of toenail levels
of Zn over a long period of time (Garland et al. 1993).
Reviewing the main physiological aspects of this heavy
metal, it is important to mention that Zn functions as a com-
ponent of various enzymes that depend on Zn for catalytic
activity (Fabris & Mocchegiani, 1995). Another biological
function of Zn is the maintenance of the integrity of proteins
Table 3. Age- and centre-adjusted levels of risk factors by quintiles (Q) of zinc among controls*
Risk factor Q1 Q2 Q3 Q4 Q5 P for trend
Age (years) 53·1 51·8 53·0 54·0 55·3 0·006
BMI (kg/m2) 25·6 25·8 25·6 26·4 26·0 0·16
Total cholesterol (mmol/l) 5·4 5·6 5·5 5·5 5·7 0·09
HDL-cholesterol (mmol/l) 1·07 1·12 1·11 1·06 1·11 0·69
Alcohol (g/week) 124·8 134·8 129·5 109·9 142·1 0·66
a-Tocopherol† (mg/g) 188·3 175·2 188·7 185·4 215·7 0·03
b-Carotene† (mg/g) 0·43 0·46 0·44 0·44 0·43 0·73
Se (mg/kg) 0·58 0·61 0·63 0·64 0·68 0·0001
History of hypertension (%) 12·6 14·9 13·0 9·3 12·8 0·67
Smoking (% current smokers) 41·0 44·5 35·3 35·3 36·3 0·19
Diabetes mellitus (%) 2·4 2·5 1·8 3·3 1·8 0·74
Family history of CHD (%) 43·5 41·9 46·8 46·2 41·3 0·76
Low socio-economic status (%) 16·6 18·2 12·8 14·5 17·1 0·96
* Cut-off values for quintiles of Zn in controls were 88·4, 96·8, 106·5 and 118·9 mg/kg (the mean value of each quintile
was 82·5, 93·1, 101·5, 111·9 and 134·6 mg/kg).
† Geometric means.
Table 4. Risk of first myocardial infarction by quintiles (Q) of zinc
(Relative risk ratios and 95 % confidence intervals)
Q1 Q2 Q3 Q4 Q5 P for trend
Cases (n) 153 124 152 132 123
Controls (n) 145 145 146 143 145
Median (mg/kg) 82·5 93·1 101·5 111·9 134·6
Model 1* 1 0·85 1·00 0·87 0·81 0·25
95 % CI 0·61, 1·18 0·73, 1·39 0·63, 1·22 0·58, 1·13
Model 2† 1 0·97 1·15 0·91 0·85 0·45
95 % CI 0·59, 1·58 0·72, 1·85 0·56, 1·50 0·52, 1·39
Model 3‡ 1 0·99 1·17 0·95 0·93 0·69
95 % CI 0·60, 1·63 0·73, 1·90 0·58, 1·57 0·56, 1·53
* Age- and centre-adjusted.
† Further adjusted by BMI, HDL-cholesterol, history of hypertension, smoking, alcohol intake, diabetes, family history
of CHD, a-tocopherol, b-carotene and Se.
‡ Further adjusted by socio-economic status.
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required for the stability of membrane structures (Henning
et al. 1999). Finally, Zn has a role as a regulator of gene
expression (Tamura et al. 1996; Archer et al. 2001).
While knowledge of the biochemical and molecular gen-
etics of Zn function is well developed and expanding, no
relationship of these genes to Zn deficiency, toxicity or
functions for which Zn is particularly critical have been
clearly established.
Zn is widely distributed in food, but the majority of Zn is
present as free ion. Therefore, its bioavailability seems to
be a function of the extent of absorption and digestion
(Prasad, 1993; Vallee & Falchuk, 1993). Almost all Zn is
absorbed by the small intestine through a transcellular pro-
cess. Considerable amounts of Zn come from endogenous
sources. Zn depletion in man is accompanied by reduced
endogenous Zn loss and an increase in the efficiency of
intestinal Zn absorption. Regulation of absorption may
provide a ‘coarse control’ of body Zn, whereas endogenous
Zn release provides ‘fine control’ to maintain balance.
In this context, circulating Zn in plasma provides an insen-
sitive index of Zn status. Moreover, plasma Zn levels are
strongly affected by acute-phase stimuli, such as acute
myocardial infarction (Craig et al. 1990; Pucheu et al.
1995). Therefore, it is far more appropriate to use toenail
Zn as a biomarker, since it has been shown to be a reliable
indicator of long-term Zn intake.
In the present study, we found up to 27 % difference in
the Zn levels among controls studied across centres. This
relatively low level of variation suggests that toenail Zn
concentrations could be affected by the homeostatic mech-
anisms (and, therefore, relatively modest differences in Zn
intake would not be easily detected), or that this particular
study population (although arising from different European
centres) shows little variability in Zn intake.
Regarding the anti-atherogenic effect of Zn, an antioxi-
dant and membrane-stabilizing effect has been hypothesized
(Henning, 1996, 1999). Experimental studies have shown
that Zn protects against metabolic physiological derange-
ments of the vascular endothelium and interferes with
signalling pathways involved in apoptosis, whereas Zn
deficiency causes an impairment of endothelial barrier func-
tion. The results of epidemiological studies are inconsistent,
although most of them found lower levels of serum Zn
levels in patients with differing manifestations of cardiovas-
cular disease than in apparently healthy controls (Manthey
et al. 1981; Khan et al. 1984; Marniemi et al. 1988; Oster
et al. 1989; Iskra et al. 1993; Martin-Lagos et al. 1997).
However, the serum levels of Zn measured in these study
designs (basically case–control studies) were analysed
after the occurrence of the cardiovascular event, where a
decrease of Zn levels is probably a non-specific secondary
manifestation of the acute-phase reaction (Craig et al.
1990; Pucheu et al. 1995).
The main epidemiological studies where the measure-
ment of serum Zn levels was carried out before the occur-
rence of the cardiovascular event were two nested
case–control studies. Both were well designed although
had somewhat different conclusions. The first reported
no significant change in the risk of death from cardiovas-
cular disease, although the authors pointed out that the
data were compatible with a protective effect of a high
Zn level (Kok et al. 1988). The second showed that
lower serum Zn was an independent predictor of cardio-
vascular death, with a relative risk of 0·57 (95 % CI
0·35, 0·93) in the highest third of serum Zn levels
(Reunanen et al. 1996).
In conclusion, our results in this multi-centre study
population suggest that toenail Zn levels, which reflect
integration of dietary Zn intake and exposure over time,
are not significantly associated with acute myocardial
infarction. It is possible that the relative homogeneity of
Zn levels and probably also intake in these populations
does not permit detection of an association. Nevertheless,
these results do not preclude the existence of an associ-
ation in populations with less homogeneous Zn levels.
For example, the Jerusalem centre, in which there was a
greater variation in intake, showed a significant within-
population protective association of higher Zn levels.
Therefore, we believe that studies in populations with
greater variability in Zn levels would be of substantial
interest.
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